DDInter898 DDInter899
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ibritumomab tiuxetan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Antithrombin Alfa
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Abciximab
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac